High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors.
OBJECTIVE
To evaluate viability of isolated peripheral blood mononuclear cells (PBMC) and production of cytokines in vitro after stimulation as prognostic factors for survival in sepsis patients.


METHODS
Prospective study of the biological response of PBMC in the onset of severe sepsis.


METHODS
Research laboratory of molecular biology and immunology and university hospital ICU, Faculty of Medicine, Trakia University.


METHODS
Twenty-three patients meeting the criteria for severe sepsis, and 14 control subjects.


METHODS
Isolated PBMC were stimulated in vitro with: C3-binding glycoprotein (C3bgp; 30 microg), lipopolysaccharide (30 microg), phytohemagglutinin (20 microg), pokeweed mitogen (30 microg), and dexamethasone (500 microg).


RESULTS
We measured the levels of interleukins (IL) 6, 10, and 12 in culture supernatants. Stimulation with C3bgp and phytohemagglutinin led to significantly lower PBMC secretion of IL-6 in nonsurvivors than in survivors and healthy donors. Stimulation with C3bgp, lipopolysaccharide, and pokeweed mitogen considerably reduced IL-12 production in nonsurvivors. Stimulation with lipopolysaccharide and pokeweed mitogen caused immune cells in nonsurvivors to produce higher levels of IL-10 than in survivors. Survival of PBMC reduced viability for nonsurvivors' PBMC, both spontaneously and as induced by lipopolysaccharide or pokeweed mitogen.


CONCLUSIONS
The viability of PBMC at the onset of sepsis and enhanced production of IL-12 and diminished production of IL-10 after stimulation with all stimuli used may be a favorable prognostic factor in sepsis.
Stanilova
Spaska A
SA
Department of Molecular Biology, Immunology, and Genetics, Faculty of Medicine, Thrakia University, Stara Zagora, Bulgaria. stanilova@mf.uni-sz.bg
Karakolev
Zhivko T
ZT
Dimov
Gospodin S
GS
Dobreva
Zlatka G
ZG
Miteva
Lyuba D
LD
Slavov
Emil S
ES
Stefanov
Chavdar S
CS
Stanilov
Noyko S
NS
D000293:Adolescent; D000328:Adult; D000368:Aged; D002470:Cell Survival; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis*; D018664:Interleukin-12 / Q000096:biosynthesis*; D015850:Interleukin-6 / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012016:Reference Values; D012680:Sensitivity and Specificity; D018805:Sepsis / Q000276:immunology* / Q000378:metabolism*; D016019:Survival Analysis
D016207:Cytokines; D015850:Interleukin-6; D016753:Interleukin-10; D018664:Interleukin-12
J Immunol. 1994 May 15;152(10):5014-21
8176219
Arch Surg. 1994 Feb;129(2):187-92
8304829
Shock. 2000 Mar;13(3):169-74
10718372
Immunol Lett. 2004 Sep;95(2):193-8
15388260
Infection. 1997 Jul-Aug;25(4):206-12
9266258
Arch Immunol Ther Exp (Warsz). 1997;45(4):277-84
9523001
Surgery. 2000 Mar;127(3):309-15
10715987
J Trauma. 1995 Jul;39(1):104-10; discussion 110-1
7636900
FASEB J. 2001 Apr;15(6):879-92
11292647
Ann Surg. 2000 Feb;231(2):253-61
10674618
Shock. 2002 Dec;18(6):487-94
12462554
Ann Surg. 2002 Apr;235(4):560-7
11923613
Int Immunopharmacol. 2001 Aug;1(8):1597-604
11515822
Infect Immun. 2001 Apr;69(4):2099-106
11254563
Crit Care Med. 2002 Sep;30(9):1987-94
12352031
Blood. 1995 Mar 1;85(5):1341-7
7858264
Int J Immunopharmacol. 2000 Jan;22(1):15-24
10684985
J Lab Clin Med. 1996 Dec;128(6):594-600
8960643
Crit Care Med. 1997 Aug;25(8):1298-307
9267941
Nat Cell Biol. 2002 Jan;4(1):26-31
11780128
Crit Care Med. 2000 Jul;28(7):2591-4
10921600
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
6606682
Ann Surg. 1996 Apr;223(4):434-40
8633923
N Engl J Med. 2003 Jan 9;348(2):138-50
12519925
J Immunol. 1997 May 1;158(9):4422-9
9127007
Crit Care Med. 1992 Jun;20(6):864-74
1597042
Intensive Care Med. 1996 Jul;22(7):707-10
8844239
Crit Care Med. 2004 May;32(5 Suppl):S202-8
15118518
Br J Dermatol. 1996 Feb;134(2):199-207
8746330
J Infect Dis. 2000 Jan;181(1):176-80
10608764
Biochem Biophys Res Commun. 1994 Jul 15;202(1):186-94
8037713
Intensive Care Med. 2004 Jun;30(6):1017-31
15170528